LAVA Therapeutics
Odijk, Netherlands
Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Prof. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California. From 2002-2017, he led research and preclinical development at Genmab where he developed antibodies incorporated in seven FDA/EMA approved therapeutics to date. He is an inventor of ofatumumab (Arzerra, 2009; KESIMPTA, 2020), daratumumab (DARZALEX, 2015), teprotumumab (Tepezza, 2020), amivantamab (RYBREVANT, 2021), tisotumab vedotin (Tivdak, 2021) and two clinically translated technologies to generate bispecific (DuoBody) and effector-function enhanced (HexaBody) antibodies. He has a strong publication record with >230 scientific publications (>34,500 citations; h factor of 99; Google Scholar Jul. 1, 2022) and 150 granted patents in US and EU). He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. In 2018, he joined LAVA Therapeutics, a biotechnology company that discovers and develops bispecific gamma-delta T cell engagers, as its Executive Vice President and Head of R&D. He provides drug development, patent and investment advice as an independent consultant from his company Sparring Bioconsult. He is the Chair of the Board of Directors of The Antibody Society.
Disclosure information not submitted.
Saturday, November 12, 2022
4:30 PM – 4:45 PM Eastern Time
